– CANADA, Toronto – BioSyent Inc. (TSX-V:RX) today announced the retirement of two long-serving Directors, Mr. Douglas Larson and Mr. Milton Wakefield, from its Board of Directors. BioSyent also announced the appointment of Mr. Larry Andrews and Ms. Sara Elford to its Board of Directors.

Messrs. Larson and Wakefield have served on the Board of Directors for 21 years and 20 years, respectively, helping to guide the Company through much challenge, transformation and growth during their tenure. “We thank Mr. Larson and Mr. Wakefield for their long service, commitment and contribution to the success of BioSyent,” remarked René Goehrum, Chairman, President and CEO of BioSyent.

Upon the retirement of Messrs. Larson and Wakefield, BioSyent is pleased to welcome Mr. Larry Andrews to its Board of Directors. Mr. Andrews is an accomplished senior executive with more than 37 years of experience in the pharmaceutical industry. Mr. Andrews was President and CEO of Cipher Pharmaceuticals, a TSX-listed Canadian pharmaceutical company, between 2004 and 2014. He previously served as President of AltiMed Pharmaceutical Company, as well as various other senior leadership roles with major pharmaceutical companies, including Hoffman La Roche, Janssen Pharmaceuticals, and Eli Lilly Canada. Mr. Andrews is also the Founder and President of The Health Alliance Group, a healthcare consulting firm. Mr. Andrews holds an Honours B.Sc. from Memorial University. Mr. Andrews recently served as a Board Director for GMD Distribution Inc., a logistics service provider for the life sciences industry, which was acquired by McKesson Canada in 2017.

BioSyent is also pleased to welcome Ms. Sara Elford to its Board of Directors. Ms. Elford brings a wealth of capital markets experience and financial expertise to the Board of Directors. She has enjoyed a long career in Canadian capital markets as a Director and Research Analyst with a major Canadian investment firm as well as in investment banking roles with Kidder Peabody and Wood Gundy. Ms. Elford is a Chartered Financial Analyst Charterholder and holds a BBA from Bishop’s University. Ms. Elford previously served as an Independent Director of Pure Technologies Ltd., a TSX-listed infrastructure technology company, and presently serves as an Independent Director of Carmanah Technologies Corporation, a TSX-listed solar lighting design and manufacturing company, and Hydrogenics Corporation, a TSX and NASDAQ-listed fuel cell and hydrogen generation design and manufacturing company.

“I am delighted to welcome two accomplished leaders, Larry Andrews and Sara Elford, to BioSyent’s Board of Directors,” commented René Goehrum. “They each bring an impressive level of experience, expertise and business acumen to the Board and I look forward to their insights as we strive to deliver continued profitable growth to our shareholders.”

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

For more information : http://www.biosyent.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Talent4Boards Team

here the original post =>

Comments are closed.